Better Screening Key to Closing U.S. 'Race Gap' in Colon Cancer Deaths

Follow Drugslib on

Medically reviewed by Drugs.com.

By Ernie Mundell HealthDay Reporter

WEDNESDAY, July 24, 2024 -- Black Americans are almost a third more likely to die from colon cancer than their white peers, and one key to closing that divide could be better cancer screening, a new report finds.

That means getting Black Americans quality colonoscopies and other forms of screening, but also making sure they're followed up after their test results come in.

"Our study shows that it's not enough to just get everyone screened; the quality of care during screening and follow-up must also be similar for Black and white adults," explained study lead author Oguzhan Alagoz. He's a professor of industrial and systems engineering at the University of Wisconsin-Madison.

The findings were published July 24 in the Journal of the National Cancer Institute.

As Alagoz' team noted, compared to whites, Black Americans are still 23% more prone to receiving a colon cancer diagnosis and about 31% more likely to die from the disease.

Some of this disparity had been blamed on lower rates of recommended colon cancer screening among Black patients versus whites. However, over the past two decades that gap has closed.

For example, in 2005, one study found that 52% of white Americans said they were up to date on their colon cancer cancer screenings, compared to to just 39% of Black people.

By 2019, however, that disparity had vanished: 69.5% of Black people and 69.8% of White people said they'd been keeping up with their screenings, the data showed.

So, why are Black Americans still dying of colon cancer at higher rates?

As the Wisconsin team noted, it's one thing to get screened and another to get proper and timely follow-up (for example, follow-up colonoscopies, biopsies) if your colon cancer screen comes back positive.

According to the researchers, Black patients do have significantly lower rates of follow-up than whites. The colonoscopy services Black patients receive tend to be of lower quality, as well.

What if those disparities were eliminated?

Using sophisticated mathematical modeling, Alagoz and colleagues calculated that if the gap in proper follow-up was eliminated, that could cut the race gap for colon cancer incidence by 5.2%, and for colon cancer deaths by 9.3%.

Making the quality of colonoscopies equal for white and Black patients would further reduce the gap in colon cancer incidence by 14.6%, and colon cancer deaths by 18.7%, the study found.

Doing both those things would result in racial disparities in colon cancer incidence shrinking by 49% overall, and the disparity in colon cancer deaths would be reduced by 59%, the team concluded.

Alagoz' group noted that these gaps wouldn't be completely eliminated, even with better screening and follow-up.

That's because other factors -- for example, racial differences in overall health and access to care -- probably play a role, as well.

All of this means that, "to truly close the racial gap in cancer deaths and achieve health equity, we need to find innovative solutions," Alagoz said in a journal news release.

Sources

  • Oxford University Press, news release, July 24, 2024

    • Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.

    Source: HealthDay

    Posted : 2024-07-24 23:15

    Read more

    Disclaimer

    Every effort has been made to ensure that the information provided by Drugslib.com is accurate, up-to-date, and complete, but no guarantee is made to that effect. Drug information contained herein may be time sensitive. Drugslib.com information has been compiled for use by healthcare practitioners and consumers in the United States and therefore Drugslib.com does not warrant that uses outside of the United States are appropriate, unless specifically indicated otherwise. Drugslib.com's drug information does not endorse drugs, diagnose patients or recommend therapy. Drugslib.com's drug information is an informational resource designed to assist licensed healthcare practitioners in caring for their patients and/or to serve consumers viewing this service as a supplement to, and not a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

    The absence of a warning for a given drug or drug combination in no way should be construed to indicate that the drug or drug combination is safe, effective or appropriate for any given patient. Drugslib.com does not assume any responsibility for any aspect of healthcare administered with the aid of information Drugslib.com provides. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.

    Popular Keywords